Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach

Critical Reviews in Oncology/Hematology

Volumn 68, Issue 1 SUPPL., 2008, Pages

  Fitzpatrick, John M ^a   Anderson, John ^b   Sternberg, Cora N ^c   Fleshner, Neil ^d   Fizazi, Karim ^e   Rébillard, Xavier ^f   Dogliotti, Luigi ^g   Conti, Giario ^h   Turesson, Ingela ⁱ   James, Nicholas ^j   Heidenreich, Axel ^k   Solsona, Eduardo ^l   Guillem, Vicente ^l   Herchenhorn, Daniel ^m   Moul, Judd ⁿ   van Moorselaar, Jeroen ^o   Coetzee, Lance J E ^p   Wilson, Andrew ^q   Bamias, Aristotelis ^r   De Wit, Ronald ^s   Chrisofos, Michael ^t   more..

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Clinique Beau Soleil   (France)

^g SAN LUIGI GONZAGA HOSPITAL   (Italy)

^h SANT ANNA HOSPITAL   (Italy)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k UNIVERSITY OF COLOGNE   (Germany)

^l INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^m INSTITUTO NACIONAL DE CÂNCER   (Brazil)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^o VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^p Pretoria Urology Hospital   (South Africa)

^q Department of Haematology and Bone Marrow Transplantation Unit   (South Africa)

^r ALEXANDRA HOSPITAL   (Greece)

^s ERASMUS MC CANCER INSTITUTE   (Netherlands)

^t SISMANOGLIO HOSPITAL   (Greece)

more..

Author keywords

Case study; Docetaxel; Hormone refractory prostate cancer; International society of geriatric oncology (SIOG); Multidisciplinary; Senior adult patients

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; GONADORELIN; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SATRAPLATIN; SILDENAFIL;

ADVANCED CANCER; AGING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CRYOSURGERY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HORMONAL THERAPY; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 50449085844     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.019     Document Type: Review

References (42)

1. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
2. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
3. Dogliotti L. Advanced prostate cancer: at last a role for medical oncologists. Eur Urol 51 (2007) 4-5
4. American Cancer Society. Cancer facts & figures 2007 (2007), American Cancer Society, Atlanta GA, USA
5. Bubolz T., Wasson J.H., and Barry M.J. Treatments for prostate cancer in older men: 1984-1997. Urology 58 (2001) 977-982
6. Zelefsky M.J., Marion C., Fuks Z., et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. J Urol 170 (2003) 1828-1832
7. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
8. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 (2006) 516-521
9. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.C., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25 (2007) 3965-3970
10. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
11. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
12. Cookson M.S., Aus G., Canby-Hagino E.D., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540-545
13. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
14. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3972-3978
15. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
16. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormone therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
17. Svatek R.S., Shulman M., Choudhary P.K., et al. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 106 (2006) 1047-1053
18. Partin A.W., Hanks G.E., Klein E.A., et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 16 (2002) 1024-1038
19. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
20. Armstrong A., Garrett-Mayer E.S., Ou Yang Y.C., De Wit R., Tannock I.F., and Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007) 6396-6403
21. Mehta A., Stein M., Goodin S., et al. Pre-treatment PSA doubling time (PSADT) predicts biochemical response to chemotherapy in patients with androgen sensitive PSA progression after local therapy. J Clin Oncol 24 18S (2006) Abstract 14528
22. Semeniuk R.C., Venner P.M., and North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 68 (2006) 565-569
23. Thuret R, Massard C, Gross-Goupil M, et al. The post chemotherapy PSA surge syndrome. Ann Oncol 2008;(March) [Epub ahead of print] doi:10.1093/annonc/mdn062.
24. Thompson I., Thrasher J.B., Aus G., et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
25. Katz M.H., and McKiernan J.M. High-risk, clinically localized prostate cancer: is monotherapy adequate?. Rev Urol 9 Suppl. 2 (2007) S19-27
26. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
27. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
28. Lorente J., Vallmanya F., Foro P., et al. Improved biochemical disease-free survival with immediate irradiation after radical prostatectomy with positive surgical margins: a match-paired analysis. ASCO Prostate (2007) [Abstract No. 185]
29. Sonpavde G., Hutson T.E., and Berry W.R. Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 32 (2006) 90-100
30. Srinivas S., Balu V., and King C. Utility of serum prostate specific antigen doubling time (PSADT) in patients with androgen independent prostate cancer. J Clin Oncol 23 16S (2005) [Abstract 4631]
31. Walczak J.R., and Carducci M.A. Phase 3 randomized trial evaluating second-line hormone therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormone therapy for prostate cancer: An Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit Study. Urology 62 (2003) 141-146
32. Beer T.M., Berry W., Wersinger E.M., et al. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2 (2003) 167-172
33. Ohlmann CH, Engelmann U, Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPCA) previously treated with docetaxel-based chemotherapy. 2006 American Society of Clinical Oncology Prostate Cancer Symposium [Abstract 248].
34. Fizazi K., Le Maitre A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8 (2007) 994-1000
35. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
36. Small E.J., Sacks N., Nemunaitis J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 3883-3891
37. Sternberg C.N., Petrylak D., Witjes F., et al. Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol 25 18S (2007) [Abstract 5019]
38. Poissonnier L., Chapelon J., and Rouviere O. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51 (2007) 381-387
39. Jo Y., Junichi H., Tomohiro F., Yoshinar I., and Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU Int 96 (2005) 43-47
40. Shipley W.U., Desilvio M., Pilepich M., et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64 (2006) 1162-1167
41. Graefen M., Karakiewicz P., Cagiannos I., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20 (2002) 3206-3212
42. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882